FHC Shareholders – How to Vote
To ensure that your shares of FHC Common Stock are voted at the special meeting, submit your proxy OR, if your shares of FHC Common Stock are held in the name of a broker, bank or other nominee, contact your broker, bank or other nominee. If you do not vote or do not instruct your broker, bank or other nominee how to vote, it will have the same effect as voting “AGAINST” the approval of the proposed merger.
For shareholders who need assistance voting their shares, or have questions regarding the special meeting, please contact FHC’s proxy solicitation firm,
To vote, you will need the control number which appears on your proxy card. If you have not received the proxy materials and voting instructions, either electronically or in the mail, contact your broker, if you have one, or
Below are two convenient ways to vote. FHC highly recommends shareholders vote electronically or by phone. Please have your control number ready while voting. The control number is located on your proxy card.
The FHC Board Recommends Shareholders Vote “FOR” all of the proposals.
FHC’s Board of Directors believes the merger is a remarkable opportunity to transform FHC into a more profitable and rapidly growing entity and urges shareholders to vote as soon as possible FOR the proposals.
The FHC Board’s rationale is straightforward. FHC is a single product company that has enjoyed a long run as the only provider of an
In order to grow and increase shareholder value, FHC must diversify its opportunities by adding products to its offering. This transaction does exactly that. APP brings multiple near-term products with extremely large market opportunities. The success of any one of APP’s products could dwarf sales of FC2. APP has strategically built a portfolio that includes four potentially lower-risk / higher-return products that utilize a regulatory approval pathway, which significantly reduces the time, cost and risk in obtaining
The full meeting agenda is detailed in FHC's definitive proxy statement, which has been filed with the
Additional Information about the Proposed Transaction and Where You Can Find It
FHC filed a definitive proxy statement with the
The proxy statement and other relevant materials, and any other documents filed by FHC with the
For more information about the
This press release contains forward-looking statements, including those regarding the proposed merger transaction between FHC and APP and the integration of our two businesses and those regarding the timing and process for regulatory approval of APP's Tamsulosin DRS. These statements are subject to known and unknown risks, uncertainties and assumptions, and if any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our actual results could differ materially from those expressed or implied by such statements. These risks and uncertainties include but are not limited to: the risk that the proposed transaction may not be completed in a timely manner or at all; the satisfaction of conditions to completing the transaction, including the ability to secure approval by a two-thirds vote of FHC’s shareholders; risks that the proposed transaction could disrupt current plans and operations; costs, fees and expenses related to the proposed transaction; risks related to the development of APP’s product portfolio, including regulatory approvals and time and cost to bring to market; risks relating to the ability of the combined company to obtain sufficient financing on acceptable terms when needed to fund development and company operations; the risk that, even if it is completed, we may not realize the expected benefits from the transaction; and other risks described in FHC’s filings with the
Contacts: Michele Greco 312.595.9123
Press Release Kari Sharp